Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vecuronium · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Rocuronium 0.6 INT, 0.1 MNT | EXPERIMENTAL | Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium. |
| Rocuronium 0.6 INT, 0.15 MNT | EXPERIMENTAL | Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium. |
| Rocuronium 0.6 INT, 0.2 MNT | EXPERIMENTAL | Participants in this group received a 0.6 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium. |
| Rocuronium 0.9 INT, 0.1 MNT | EXPERIMENTAL | Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.1 mg/kg maintenance dose of rocuronium. |
| Rocuronium 0.9 INT, 0.15 MNT | EXPERIMENTAL | Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.15 mg/kg maintenance dose of rocuronium. |
| Rocuronium 0.9 INT, 0.2 MNT | EXPERIMENTAL | Participants in this group received a 0.9 mg/kg intubating dose of rocuronium followed by 0.2 mg/kg maintenance dose of rocuronium. |
| Vecuronium 0.1 INT, 0.025 MNT | ACTIVE_COMPARATOR | Participants in this group received a 0.1 mg/kg intubating dose of vecuronium followed by 0.025 mg/kg maintenance dose of vecuronium. |
| Name | Type | Description |
|---|---|---|
| Rocuronium 0.6 mg/kg intubating dose | DRUG | Rocuronium 0.6 mg/kg intubating dose |
| Rocuronium 0.9 mg/kg intubating dose | DRUG | 0.9 mg/kg intubating dose of rocuronium |
| Rocuronium 0.1 mg/kg maintenance dose | DRUG | Rocuronium 0.1 mg/kg maintenance dose following the intubating dose. |
| Rocuronium 0.15 mg/kg maintenance dose | DRUG | Rocuronium 0.15 mg/kg maintenance dose following the intubating dose |
| Rocuronium 0.2 mg/kg maintenance | DRUG | Rocuronium 0.2 mg/kg maintenance dose following the intubating dose |
| Vecuronium 0.1 mg/kg intubating dose | DRUG | Vecuronium 0.1 mg/kg intubating dose |
| Vecuronium 0.025 mg/kg maintenance dose | DRUG | Vecuronium 0.025 mg/kg maintenance dose following the intubating dose |
Inclusion criteria: * at least 20 but under 65 years of age * American Society of Anesthesiologists (ASA) Class 1, 2 or 3 for general elective surgery * not considered to be pregnant * scheduled for elective surgery under sevoflurane or propofol anesthesia with an anticipated duration of about 1.5-...
Vecuronium is used as a muscle relaxant in anesthesia, where it is given at an intubating dose of 0.1 mg/kg to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgical procedures. It is a small molecule neuromuscular blocking agent developed by Merck & Company, Inc.
Vecuronium targets nicotinic acetylcholine receptors, specifically the CHRNA1, CHRNG, CHRNB1, CHRND, and CHRNE subunits. It acts as an antagonist at these receptors, blocking acetylcholine signaling at the neuromuscular junction to produce skeletal muscle relaxation during anesthesia.
Vecuronium is developed by Merck & Company, Inc., which trades under the ticker MRK. The company is listed as the developer of the vecuronium intubating dose product used in anesthesia.
Vecuronium is in Phase 3 development for anesthesia. The clinical program includes one completed Phase 3 trial, and no active trials are currently listed. The drug is investigational in this development context rather than newly approved.
Vecuronium has been studied in the Phase 3 trial NCT00970762, titled Comparative Study of Rocuronium With Vecuronium (Study 71101). That trial is completed, enrolled 90 participants, used an active-controlled randomized design, and included patients aged 20 years and older.